Drugs / NB-4746
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07369076 | Mar 2026 → Apr 2027 expected | amyotrophic lateral sclerosis | Nura Bio | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-08-25 | Nura Bio | Nura Bio Initiates Phase I Clinical Trial for its Oral, Brain-Penetrant SARM1 Inhibitor, NB-4746 nurabio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NB-4746 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07369076 ↗ |
| Route | Oral | “take by mouth twice daily” NCT07369076 ↗ |